The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.
Age ≥ 18 years
Current or prior diagnosis of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer, renal cancer, melanoma, or sarcoma
Ability to understand spoken or written English or Spanish in a healthcare context
Ability to understand and the willingness to sign a written informed consent document
Prior cancer genetic testing
Prior germline genetic testing
Active hematologic malignancy (e.g. chronic lymphocytic leukemia)
Currently pregnant
Dana-Farber Cancer Institute
Lead sponsor
National Cancer Institute (NCI)
Collaborator
National Human Genome Research Institute (NHGRI)
Collaborator